Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Mar
05
Today In Oncology
Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes
CD123-Targeting ADC Shows Activity in AML and BPDCN
Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds
Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence
Research Suggests AI Pathology Models May Take Unreliable Shortcuts to Identify Cancer Biomarkers
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo